Anuh Pharma Limited has informed the Exchange regarding the approval of Un-audited Financial Results for the quarter ended December 31, 2025 and Granting Authorization to Key Managerial Personnel for determination of materiality of events/ information under Regulation 30(5) of SEBI (LODR) Regulations, 2015.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anuh Pharma Limited has approved its unaudited financial results for the quarter ended December 31, 2025 (Q3 FY26). The specific financial numbers were not disclosed in the filing notice itself, but the board has formally cleared the results. Separately, the company has authorized its Key Managerial Personnel to determine which events or information qualify as material for disclosure to the stock exchanges, as required under Regulation 30(5) of SEBI's Listing Obligations and Disclosure Requirements. This is a routine governance and compliance update with no disclosed corporate action.
No direct material impact on shareholders or stock price from this notice alone, as it is a procedural filing confirming board approval of results and a governance housekeeping measure. Investors should look at the actual financial results document for the real numbers and business performance.